TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02458053

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attends with partner
Description: The index partner will participate in intervention as a couple with their female counterpart.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples Skill Training
Description: Participants and their partners will attend a pre session covering topics to assist them in working together to facilitate lifestyle changes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face to face group sessions
Description: Group sessions will consists of components in traditional weight management programs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face to face group sessions
Description: Group sessions will consists of components in traditional weight management programs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Monitor
Description: Participants will be instructed to monitor their eating and physical activity behaviors online/mobile application.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self Monitor
Description: Participants will be instructed to monitor their eating and physical activity behaviors online/mobile application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Notebook
Description: The notebook will consist of behavioral lessons, diet and physical activity plans, and additional resources to assist participants in achieving their behavioral goals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Notebook
Description: The notebook will consist of behavioral lessons, diet and physical activity plans, and additional resources to assist participants in achieving their behavioral goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: Each participant will receive a tailored email providing feedback on their weekly progress.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feedback
Description: Each participant will receive a tailored email providing feedback on their weekly progress.
Study: NCT02171442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 953 ZW Intravenously
Description: 5 mg, 2.8 MBq (76 µCi)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBR 1048 Oral Solution
Description: 200 mg free base, 2.8 MBq (76 µCi)
Study: NCT01743443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cochet-Bonnet esthesiometer central corneal sensitivity
Description: Using the Cochet-Bonnet esthesiometer central corneal sensitivity was measured preoperatively, after 7 days, and once a month after surgery until recovery of the baseline preoperative level. Normal levels of central corneal sensitivity were considered above 40mm.
Study: NCT02866227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOL-463
Description: TOL-463 vaginal gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOL-463
Description: TOL-463 vaginal insert
Study: NCT03528226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training Procedure
Description: Exercise training: 3 sessions - 2 supervised and 1 unsupervised - per week of 30-60 min at 65% - 80% of maximum heart rate (4 months)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Normal life procedure
Description: No supervised exercise training during the 4 month period.
Study: NCT01187485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androderm® 2.5mg
Description: Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androderm® 5.0mg
Description: Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androderm® 7.5mg
Description: Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
Study: NCT02184923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: presentation of visual vertical
Study: NCT03018613

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Transplantation and the traditional treatments for chronic functional constipation in part 1.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline and the traditional treatments for chronic functional constipation in part 2
Study: NCT03148041

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: health education program
Description: Intensive health education program for intervention group: 1.The introductory 30 minute Arabic lecture for increase level of the awareness of the participants regarding stroke. Lecture from the USA National Stroke Association, 2011, will be used. The lecture includes the following issues about stroke (1) definition; (2) signs and symptoms; (3) risk factors; (4) treatment; and (5) prevention.~2. Self-help materials will involve health education brochures regarding stroke and will be distributed for all participants at the time they are attending the lecture. The brochures which will be used for this study will be collected from the World Stroke Day 2016 Brochures, the Arabic version.~The routine care for control group: different lecture and brochures will be used

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: health education program
Description: Intensive health education program for intervention group: 1.The introductory 30 minute Arabic lecture for increase level of the awareness of the participants regarding stroke. Lecture from the USA National Stroke Association, 2011, will be used. The lecture includes the following issues about stroke (1) definition; (2) signs and symptoms; (3) risk factors; (4) treatment; and (5) prevention.~2. Self-help materials will involve health education brochures regarding stroke and will be distributed for all participants at the time they are attending the lecture. The brochures which will be used for this study will be collected from the World Stroke Day 2016 Brochures, the Arabic version.~The routine care for control group: different lecture and brochures will be used
Study: NCT04974801

Intervention type: DEVICE
Group type: OTHER
Intervention: Provox Life
Description: Use of Provox Life range of HMEs for different situations and their attachments (adhesives and laryngectomy tubes)

Intervention type: DEVICE
Group type: OTHER
Intervention: Provox Life
Description: Use of Provox Life range of HMEs for different situations and their attachments (adhesives and laryngectomy tubes)

Intervention type: DEVICE
Group type: OTHER
Intervention: Usual Care
Description: Continued Usual Care routines.

Intervention type: DEVICE
Group type: OTHER
Intervention: Usual Care
Description: Continued Usual Care routines.
Study: NCT01156714

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treadmill training with aerobic exercise
Description: walk on treadmill for aerobic exercise
Study: NCT02907359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment Choice
Description: * BSC: according to standard/institutional practice; included RBC or platelet transfusions; growth factors, i.e. erythropoiesis stimulating agents, granulocyte stimulating factors, iron chelating therapy; broad spectrum antibiotics and/or antifungals.~* LDAC: 20 mg/m\^2 SC or IV once daily (QD) for 14 days in 28-day cycles. Other schedules were allowed per institutional practice. Treatment for ≥4 cycles absent disease progression/toxicity. BSC per institutional/standard practice.~* Standard Intensive Chemotherapy: recommended regimen of 7+3 was given as cytarabine 100-200 mg/m\^2/day continuous infusion for 7 days and an anthracycline for 3 days. Anthracyclines per institutional practice included daunorubicin (45-60 mg/m\^2/day) or idarubicin (9-12 mg/m\^2/day) or mitoxantrone (8-12 mg/m\^2/day) by IV infusion. Participants with complete or partial response after IC induction received ≥1 additional cycles with reduced cytotoxic doses then BSC per standard /institutional practice.
Study: NCT03517527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT03492333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten free diet
Description: Gluten-free diet- Instructions provided by a dietitian
Study: NCT04601688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Ophthalmic and Intravitreal Dexamethasone
Description: Pro re nata patients with BRVO will initially receive Bevacizumab and intravitreal Dexamethasone. And then depending on their clinical status of BRVO, Bevacizumab will be injected.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab Ophthalmic
Description: Pro re nata patients with BRVO will receive Bevacizumab. And then depending on their clinical status of BRVO, Bevacizumab will be injected.
Study: NCT00919607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine fumarate extended-release
Description: 300mg,oral,single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine fumarate extended-release
Description: 300mg,oral,single dose
Study: NCT00690534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside
Description: variable rate for 3 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside
Description: variable rate for 3 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside
Description: variable rate for 3 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside
Description: variable rate for 3 hours

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mixed meal
Description: mixed meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mixed meal
Description: mixed meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mixed meal
Description: mixed meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mixed meal
Description: mixed meal
Study: NCT00490113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxamine
Description: Two 250 mg capsules, or placebo, given twice a day for four, 4 week periods. Subjects with primary hyperoxaluria will aslo receive escalated doses up to 3500 mg/day for up to 6 1/2 days.
Study: NCT02637466

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vortioxetine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Study: NCT04177862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Sufentanil
Description: 30 mcg of sublingual sufentanil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Fentanyl
Description: 50 mcg of IV fentanyl
Study: NCT04640168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Baricitinib is a Janus kinase (JAK) inhibitor with the chemical name \[1-(ethylsulfonyl)-3-(4-(7Hpyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl\]acetonitrile. Each tablet contains 2 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, ferric oxide, lecithin (soya), polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone Sodium Phosphate Injection, USP, is an adrenocortical steroid anti-inflammatory drug. It is a water-soluble inorganic ester of dexamethasone. Each mL contains dexamethasone sodium phosphate equivalent to dexamethasone phosphate 4 mg or dexamethasone 3.33 mg; benzyl alcohol 10 mg added as preservative; sodium citrate dihydrate 11 mg; sodium sulfite 1 mg as an antioxidant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching oral baricitinib or intravenous dexamethasone.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching oral baricitinib or intravenous dexamethasone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Drug remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Drug remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
Study: NCT04435873

Intervention type: OTHER
Intervention: Survey using Your Home Dialysis Care Experience tool.
Description: Validation of a new survey instrument to capture the experience of care by home dialysis patients.

Intervention type: OTHER
Intervention: Survey using Your Home Dialysis Care Experience tool.
Description: Validation of a new survey instrument to capture the experience of care by home dialysis patients.
Study: NCT04433208

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Complex oligosaccharide
Description: Complex oligosaccharide concentrate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Complex oligosaccharide
Description: Complex oligosaccharide concentrate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic
Study: NCT01391065

Intervention type: RADIATION
Group type: OTHER
Intervention: MR PET Guided Brachytherapy
Study: NCT01545921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality Of Life questionnaires completion
Description: Before randomization, all patients will have to complete questionnaires in this order : QLQ-C15-PAL, MVQOLI and QUAL-E.~MVQOLI and QUAL-E will be completed again 3 days after the first completion at baseline. After this second QoL assessment, the order will be modified according to patient's randomisation : arm A, B, C or D.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality Of Life questionnaires completion
Description: Before randomization, all patients will have to complete questionnaires in this order : QLQ-C15-PAL, MVQOLI and QUAL-E.~MVQOLI and QUAL-E will be completed again 3 days after the first completion at baseline. After this second QoL assessment, the order will be modified according to patient's randomisation : arm A, B, C or D.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality Of Life questionnaires completion
Description: Before randomization, all patients will have to complete questionnaires in this order : QLQ-C15-PAL, MVQOLI and QUAL-E.~MVQOLI and QUAL-E will be completed again 3 days after the first completion at baseline. After this second QoL assessment, the order will be modified according to patient's randomisation : arm A, B, C or D.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality Of Life questionnaires completion
Description: Before randomization, all patients will have to complete questionnaires in this order : QLQ-C15-PAL, MVQOLI and QUAL-E.~MVQOLI and QUAL-E will be completed again 3 days after the first completion at baseline. After this second QoL assessment, the order will be modified according to patient's randomisation : arm A, B, C or D.
Study: NCT01156714

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Memory training with computerized memory program
Description: memory testing and training on computer program
Study: NCT02005302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1,25(OH)2 Vitamin D3
Description: Oral 1,25(OH)2 Vitamin D3 by 0.25 microgram once daily at start and regulate the dose according to the changes of blood levels of 25(OH)Vit D, calcium, phosphorus, and intact parathyroid hormone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D2
Description: Oral Vit D2 1.25mg(50,000 unit) once weekly as a start and maintain 1.25mg(50,000 unit) once monthly according to the blood 25(OH)vitamin D level.
Study: NCT01156714

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Combination of treadmill training and computerized memory
Description: both exercise and cognitive computer training
Study: NCT02005302

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low protein diet
Description: Using nutritious software to make meals recipes and give dietary guidance for patients to reach the DPI goal of 0.6g-0.8g/kg/d.
Study: NCT02959359

Intervention type: DRUG
Group type: OTHER
Intervention: Ledipasvir 90mg/Sofosbuvir 400 mg
Description: A 12 week Harvoni (Ledipasvir 90mg/Sofosbuvir 400 mg ) plus ribavirin will be provided after confirmation of curative treatment.

Intervention type: DRUG
Group type: OTHER
Intervention: Ribavirin
Description: A 12 week Harvoni (Ledipasvir 90mg/Sofosbuvir 400 mg ) plus ribavirin will be provided after confirmation of curative treatment.
Study: NCT00561288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: 2 x 1000 mg doses per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: cornstarch
Description: 2 x 1000 mg cornstarch per day
Study: NCT01692977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychological assessment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neuropsychological assessment
Study: NCT02784847

Intervention type: DRUG
Group type: OTHER
Intervention: Triheptanoin
Description: Triheptanoin oil administered three times per day during meals at a total dose 1mg/kg/day for 3 months
Study: NCT00673335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT06060795

Intervention type: DIAGNOSTIC_TEST
Intervention: Electro-conductance measurement
Description: Interventions are done to diagnose Autonomic Nervous system Troubles

Intervention type: DIAGNOSTIC_TEST
Intervention: Electro-conductance measurement
Description: Interventions are done to diagnose Autonomic Nervous system Troubles
Study: NCT01390922

Intervention type: DRUG
Intervention: Botulinum Toxin Type A
Description: Botulinum Toxin Type A
Study: NCT00657982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 10mg BID
Study: NCT00786799

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fatty Acids
Description: Omega-3's are administered in the form of an orange pudding made by Coromega~1 mg of omega-3 fatty acid 2 times per day
Study: NCT02005302

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: normal protein diet
Description: Using nutritious software to make meals recipes and give dietary guidance for patients to reach the DPI goal of more than 0.8g/kg/d.
Study: NCT04123938

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea Protein
Description: Soluble pea protein
Study: NCT02770534

Intervention type: PROCEDURE
Intervention: blood test
Description: 10mls extra mls of blood taken during usual phlebotomy procedures
Study: NCT04123938

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein
Description: Whey protein concentrate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Non-protein isocaloric comparator
Study: NCT03168672

Intervention type: DEVICE
Group type: OTHER
Intervention: Global ICON
Description: The study device is the GLOBAL ICON stemless humeral component, consisting of the Anchor Plate and Humeral Head.
Study: NCT03037788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WO3979
Description: Application of cream to each axilla

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WO3970
Description: Application of cream to each axilla

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WO3992
Description: Application of cream to each axilla

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (WO3988)
Description: Application of cream to each axilla
Study: NCT03397290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) Imaging
Description: Ultrasound (US) Imaging will be compared to the chest X-ray for diagnostic accuracy (sensitivity and specificity) in diagnoses of pneumothorax post transthoracic lung biopsy
Study: NCT00131235

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulfadoxine-pyrimethamine treatment twice during pregnancy
Description: Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks.~2 placebo tablets for azithromycin taken at the same time points.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine at 4-week intervals
Description: Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and then at 4 week intervals until 37.0 gestation weeks.~2 placebo tablets for azithromycin taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice
Description: Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and then at 4 week intervals until 37.0 gestation weeks.~2 azithromycin tablets (each 500 mg) taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks.
Study: NCT04282356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy during surgery
Description: During interval surgery the patient will undergo HIPEC (Cisplatin 100mg/m2, 1h 30 infusions with sodium thiosulfate renal protection). They will then receive postoperative IPC i.e intravenous and intraperitoneal administration (IV Paclitaxel, 135mg/m2 on D1, IP Carboplatin, AUC 6 on D1, and IP Paclitaxel, 60mg/m2 on D8) with at least 3 courses performed (up to 4-6 allowed).
Study: NCT05430828

Intervention type: DRUG
Intervention: Repatha (evolocumab); Praluent (alirocumab)
Description: Dosage form: Injection
Study: NCT01256710

Intervention type: DEVICE
Intervention: Trifecta™ aortic bioprosthesis
Description: Surgical aortic valve replacement with the Trifecta™ valve.